Viatris reported $1.16B in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Celltrion KRW 218.78M 1.5M Sep/2025
Cspc Pharmaceutical CNY 11.52B 486M Jun/2025
Deva Holding AS TRY 200.02M 0 Sep/2023
Dianthus Therapeutics USD 42.85M 42.82M Sep/2025
Divis Laboratories Ltd INR 265.47M 264.53M Sep/2025
Kangmei Pharma CNY 13.86B 0 Jun/2025
Knight Therapeutics CAD 539.32M 1.63M Sep/2024
Laboratorios Farma EUR 51.82M 1.55M Dec/2023
Malin Corporation EUR 200K 0 Dec/2024
Medical Developments International AUD 115.01M 9.28M Dec/2024
Neuren Pharmaceuticals AUD 165.27M 10.43M Dec/2024
Organigram Holdings CAD 134.46M 438.86K Sep/2025
Ovoca Bio EUR 11.06M 0 Jun/2022
Pharma Mar EUR 17.58M 0 Sep/2025
Qiagen NV USD 216.56M 284.67K Dec/2025
Sartorius EUR 69.04M 0 Sep/2025
Sino Biopharmaceutical CNY 17.89B 30.5M Jun/2025
Tilray USD 1.06B 86.93M Mar/2025
Viatris USD 1.16B 6.55M Sep/2025
Zz Pientze Pharmaceu CNY 603.32M 0 Sep/2025